ArticleSeminars in dialysis
Management of Polypharmacy in Dialysis Patients.
Article in Seminars in dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03663049. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trial of Statin Holiday in Patients Receiving Maintenance Dialysis
Who cites it
38 citing papers in PubMed.
- Trial
- Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia.Scientific reports · 2023Trial
- Effectiveness of using STOPP/START criteria to identify potentially inappropriate medication in people aged ≥ 65 years with chronic kidney disease: a randomized clinical trial.European journal of clinical pharmacology · 2019Trial
- Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Determination of drug-related problems according to PAIR criteria in dialysis patients: a cross-sectional study in tertiary care hospital.BMC pharmacology & toxicology · 2024Observational
- Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis.JAMA network open · 2024Article
- The Value of Pharmacogenomics for White and Indigenous Americans after Kidney Transplantation.Pharmacy (Basel, Switzerland) · 2023Article
- QT-Prolonging Antibiotics, Serum-to-Dialysate Potassium Gradient, and Risk of Sudden Cardiac Death Among Patients Receiving Maintenance Hemodialysis.Kidney medicine · 2023Article
- The Future of Drug Delivery.Chemistry of materials : a publication of the American Chemical Society · 2023Article
- Balancing Risk and Uncertain Benefit in Pharmacotherapy for Pain in Kidney Transplant Recipients.Clinical journal of the American Society of Nephrology : CJASN · 2023Article
- Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure.Kidney international · 2022Article
- Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.Health technology assessment (Winchester, England) · 2022Review
- Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.Pharmacoepidemiology and drug safety · 2022Article
- De-Prescribing Proton Pump Inhibitors in Patients With End Stage Kidney Disease: A Quality Improvement Project.Canadian journal of kidney health and disease · 2022Article
- Polypharmacy and Mental Health Issues in the Senior Hemodialysis Patient.Frontiers in psychiatry · 2022Review
- Article
- Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis.Scientific reports · 2021Article
- Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls.Clinical kidney journal · 2021Article
- [Frailty in renal diseases].Zeitschrift fur Gerontologie und Geriatrie · 2021Review
- Do Brief Mindfulness Interventions (BMI) and Health Enhancement Programs (HEP) Improve Sleep in Patients in Hemodialysis with Depression and Anxiety?Healthcare (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients receiving dialysis have other common chronic conditions in addition to end-stage renal disease, including hypertension, diabetes, cardiovascular disease, and mineral and bone disorder, all of which require long-term medication management. Dialysis patients take an average of 10-12 prescribed and over-the-counter medications from an average of 4.7 prescribers, and an average of 19 pills per day. Thus, reducing polypharmacy is not adequate as a medication therapy goal for these patients. Instead, the dialysis community should focus on ensuring that all patients receive medications that are appropriate, effective, safe and convenient. Barriers to this include a fragmented health care system with inadequate communication between multiple prescribers and pharmacies, and frequent care transitions between ambulatory care sites (dialysis centre, ambulatory primary care practice, ambulatory specialty practice) and the hospital, skilled nursing facility or long-term care facility. Three distinct processes are necessary to prevent and solve the resultant medication-related problems (and reduce polypharmacy). These are medication reconciliation (creating an accurate medication list that reflects all medications the patients is taking and how they are being taken), medication review (evaluating the list for appropriateness, effectiveness, safety and convenience in conjunction with the patient's health status), and ongoing patient-centred medication therapy management (e.g., developing treatment plans centred on each patient's medication-related goals). A team approach including pharmacists as part of the dialysis team with the dialysis facility as the primary medication home is needed.
Indexed as
Identifiers
25864928What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.